(Updates Pfizer, Novavax, Bharat Biotech, Clover, CureVac, CanSino Biologics) Nov 9 (Reuters) - Pfizer and German partner BioNTech on Monday became the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine, priming it for possible speedy regulatory approvals. Moderna and AstraZeneca, are the other frontrunners in the race to successfully develop a safe and effective COVID-19 vaccine. There are 47 vaccine candidates in human trials worldwide. The following table tracks the latest developments from major drugmakers and research institutes that have moved beyond testing their vaccine candidates in early-stage trials: For a separate FACTBOX on vaccines in final stages of development, click, and for a FACTBOX on treatments under development, click Company State of play Development phase AstraZeneca U.S. trial resumed after a Late-stage trials probe into a patient's illness; vaccine produces immune response in both young and old adults Sinopharm Prelim data from late-stage Late-stage trials underway in China, Brazil trial in Brazil showed vaccine and Bahrain; UAE grants emergency approval candidate is safe Pfizer and BioNTech The companies said vaccine was Pfizer expects to seek broad U.S. emergency SE more than 90% effective and use authorization of vaccine for people aged they have so far found no 16 to 85 in coming weeks serious safety concerns Moderna Inc Completed enrollment of 30,000 30,000-subject final stage trial began on subjects in a late-stage July 27 trial. Interim results from the trial expected in November Sinovac Biotech CoronaVac approved for Late stage trials in Brazil, Indonesia and emergency use in China to Turkey underway; Prelim data expected in vaccinate high-risk groups November CanSino Biologics Early results showed vaccine Vaccine candidate in final-stage trials, has is safe been approved for use by the Chinese military. Late-stage trial underway in Pakistan and Mexico Inovio Pharma U.S. health regulator pauses Company aims to respond to FDA's queries in company's plans to start final October trials as agency seeks more information Moscow's Gamaleya Research Russia has temporarily stopped Vaccine, approved in Russia, produced Institute vaccinating new volunteers in antibody response in all participants in its COVID-19 vaccine trial early-stage trials Vector Institute in Siberia A second Russian vaccine, Early-stage trial developed was granted regulatory approval in the country on Oct. 14. Chongqing Zhifei Biological Unit Anhui Zhifei Longcom Mid-stage trial Products Biopharmaceutical has begun human trials Bharat Biotech Vaccine candidate found to be Plans to enroll about 25,000 to 26,000 safe in early-to-mid stage participants in around 12-14 states for trials; Plans to launch its late-stage trials COVID-19 vaccine candidate in Q2, 2021 Johnson & Johnson Large U.S. vaccine trial set Results from the trial expected by the end of to resume after it was paused 2020 or early 2021 due to illness in a study volunteer. Brazil authorizes resumption of clinical trial Novavax On track to start late-stage Late-stage study underway in UK trial in U.S. in November, vaccine candidate gets FDA 'fast track' status GlaxoSmithKline First data on the vaccine it Early-to-mid stage trial is developing with Sanofi is expected by the end of the year CureVac Vaccine produces immune Plans to launch final stage of testing response in humans involving about 30,000 participants before year end Clover Biopharmaceuticals Chinese developer to receive Early-stage trials; Plans to conduct up to $328 mln from an late-stage clinical trials in Philippines epidemic response group Genexine South Korean company has begun Early-stage trials human trials Not applicable Institute of Medical Biology Mid-stage trials at Chinese Academy of Medical Sciences testing a vaccine Walvax Biotechnology Trials sponsored by Walvax and Mexico to conduct late-stage trials a Chinese military research institute, have begun The following table lists vaccines whose development timeline slightly lags the rest: Medicago Early-stage trials Cadila Healthcare Early-stage trials Not applicable Early-stage testing (bit.ly/2Eo5iDg) Arcturus Therapeutics Early-stage testing and Duke-NUS Osaka University, AnGes, Early-stage testing (bit.ly/3gaEiFB) Takara Bio Kentucky Bioprocessing Early-stage testing planned (bit.ly/2BJDU1M) Vaxine Pty/Medytox Early-stage testing Medigen Vaccine Biologics Early-stage trial (bit.ly/2XbnAOS) Corp/NIAID/Dynavax Merck & Co Early-stage trial planned ReiThera/Leukocare/Univerce Early-stage trial (bit.ly/2YgDJmo) lls Cuba's Instituto Finlay de Early-stage trial (bit.ly/3gsMu35) Vacunas Merck's unit/Institute Early-stage trial (bit.ly/3lhUhVa) Pasteur/University of Pittsburg CVR Research Institute for Early-mid stage trials (bit.ly/3jOYIFc) Biological Safety Problems, Rep of Kazakhstan West China Hospital, Early-stage trials (bit.ly/3jK7CUE) Sichuan University Beijing Wantai Biological Early-stage trials (bit.ly/3cmG9FZ) Pharmacy/Xiamen University COVAXX Early-stage trials in Taiwan University Hospital Early-stage studies (bit.ly/3iQTE3i) Tuebingen Institute of Biotechnology, Early-stage studies (bit.ly/2FQy2Wv) Academy of Military Medical Sciences, PLA of China Germany's IDT Biologika Early-stage trial Vaxart Inc Early-stage trial Imperial College London Early-stage trials SpyBiotech/ Serum Institute Early-stage trials of India (Reporting by Vishwadha Chander and Manas Mishra in Bengaluru; Editing by Maju Samuel and Shounak Dasgupta)
Our Standards: The Thomson Reuters Trust Principles.